Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
aTyr Pharma, Inc. (ATYR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.38, with a market capitalisation of $38.12M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.38 to $1.20. This page covers its latest market performance, valuation, price trends and company information.
$38.12M | |
$0.39 | |
$7.29 | |
$0.38 | |
$0.39 | |
10.11K | |
1.29M | |
-- | |
$1.20 | |
$0.38 | |
-- | |
-- |
aTyr Pharma, Inc. (ATYR) is trading at $0.38 in pre-market trading as of 2026-09-16 12:06:00, down 1.34% ($0.01) from the previous close of $0.39
Pre-market trading shows how investors are pricing ATYR before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, aTyr Pharma, Inc. (ATYR) moved from $0.50 to $0.38, representing a decline of 22.78% ($0.11).
The stock traded between $0.38 and $0.51 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 979.77 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.1%
ATYR is currently trading at $0.38, placing it 1.1% of the way from its 52-week low of $0.38 to its 52-week high of $1.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 58 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of aTyr Pharma, Inc. (ATYR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.